Management of rheumatic diseases during pregnancy

Postgraduate Medicine

Volumn 122, Issue 3, 2010, Pages 213-221

  Elliott, Amy B ^a   Chakravarty, Eliza F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ankylosing spondylitis; Outcomes; Pregnancy; Psoriatic arthritis; Rheumatic diseases; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CALCIPOTRIOL; COAL TAR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETRETIN; GLUCOCORTICOID; HYDROXYCHLOROQUINE; LA ANTIBODY; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID ANTIBODY; PLACEBO; PREDNISONE; RO ANTIBODY; SALAZOSULFAPYRIDINE; TAZAROTENE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT;

AMENORRHEA; ANKYLOSING SPONDYLITIS; ARTICLE; BREAST FEEDING; CESAREAN SECTION; CONGENITAL HEART BLOCK; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG CHOICE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; LOW BIRTH WEIGHT; LOW DRUG DOSE; OSTEOPOROSIS; PATIENT COUNSELING; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PREMATURE OVARIAN FAILURE; PREMATURITY; PREVALENCE; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; REMISSION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; DELIVERY; FEMALE; MATERNAL CARE; PREGNANCY COMPLICATION;

ANTIRHEUMATIC AGENTS; BREAST FEEDING; DELIVERY, OBSTETRIC; FEMALE; HUMANS; PRECONCEPTION CARE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RHEUMATIC DISEASES;

EID: 77953118489     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.05.2160     Document Type: Article

References (55)

1. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health. 2006;38(2):90-96.
2. Symons DP. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol. 2002;16(5):707-722.
3. Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006;54(3):899-907.
4. Katz PP. Childbearing decisions and family size among women with rheumatoid arthritis. Arthritis Rheum. 2006;55(2):217-223.
5. Golding A, Haque UJ, Giles JT. Rheumatoid arthritis and reproduction. Rheum Dis Clin North Am. 2007;33(2):319-343.
6. de Man Y, Dolhain RJ, van de Geijn FE, Willemsen SP, Hazes JM. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum. 2008;59(9):1241-1248.
7. Barrett JH, Brennan P, Fiddler M, Silman AJ. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum. 1999;42(6):1219-1227.
8. Nelson JL, Hughes KA, Smith AG, Nisperos BB, Branchaud AM, Hansen JA. Maternal-fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N Engl J Med. 1993;329(7):466-471.
9. Ostensen M, Lockshin M, Doria A, et al. Update on safety during pregnancy of biological agents and some immunosuppressive antirheumatic drugs. Rheumatology (Oxford). 2008;47(suppl 3):iii28-iii31.
10. Skomsvoll JF, Ostensen M, Irgens LM, Baste V. Obstetrical and neonatal outcome in pregnant patients with rheumatic diseases. Scand J Rheumatol Suppl. 1998;107:109-112.
11. Bowden AP, Barrett JH, Fallow W, Silman AJ. Women with inflammatory polyarthritis have babies of lower birth weight. J Rheumatol. 2001;28(2):355-359.
12. Chambers CD, Johnson DL, Jones KL. Pregnancy outcome in women exposed to anti-TNF-alpha medications: The OTIS rheumatoid arthritis pregnancy study. Abstract 1224. Arthritis Rheum. 2004;50:S479.
13. de Man YA, Hazes JM, van der Heide H, et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum. 2009;60(11):3196-3206.
14. Ostensen M. The influence of pregnancy on blood parameters in patients with rheumatic disease. Scand J Rheumatol. 1984;13(3):203-208.
15. Barrett JH, Brennan P, Fiddler M, Silman A. Breastfeeding and postpartum relapse in women with rheumatoid and inflammatory arthritis. Arthritis Rheum. 2000;43(5):1010-1015.
16. Aho K, Heliövaara M. Risk factors for rheumatoid arthritis. Ann Med. 2004;36(4):242-251.
17. Zoli A, Lizzio MM, Ferlisi EM, et al. ACTH, cortical and prolactin in active rheumatoid arthritis. Clin Rheumatol. 2002;21(4):289-293.
18. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11(3):229.
19. Carbone LD, Cooper C, Michet CJEA. Ankylosing spondylitis in Rochester, Minnesota, 1935-1989. Is the epidemiology changing? Arthritis Rheum. 1992;35(12):1476-1482.
20. Ostensen M, Husby G. A prospective clinical study of the effect of pregnancy on rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum. 1983;26(9):1155-1159.
21. Ostensen M, Ostensen H. Ankylosing spondylitis-female aspect. J Rheumatol. 1998;25(1):120-124.
22. Ostensen M, Husby G. Ankylosing spondylitis and pregnancy. Rheum Dis Clin North Am. 1989;15(2):241-254.
23. Ostensen. The effect of pregnancy on ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis. Am J Reprod Immunol. 1992:28(3-4);235-223.
24. Ghozlani I, Ghazi M, Nouijai A. Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone. 2009;44(5):772-776.
25. Geusens P, Vosse D, van der Linden S. Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol. 2007;19(4):335-339.
26. Cooper C, Carbone L, Michet CJ, Atkinson EJ, O'Fallon WM, Melton LJ 3rd. Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol. 1994;21(10):1877-1882.
27. Jang JY, Lee JG, Jeong IK, et al. A case of post-pregnancy osteoporosis combined with ankylosing spondylitis. Rheumatol Int. 2009;29(11):1359-1362.
28. Allali A. case of post-pregnancy osteoporosis-related spinal fractures in association with ankylosing spondylitis. Clin Rheumatol. 2005;24(4):435-436.
29. Buhimschi CS, Buhimschi IA, Malinow AM, Weiner CP. Intrauterine pressure during the second stage of labor in obese women. Obstet Gynecol. 2004;103(5 pt 1):225-230.
30. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34(3):J314-J321.
31. Horn EJ, Chambers CD, Menter A, Kimball AB; International Psoriasis Council. Pregnancy outcomes in psoriasis: why do we know so little? J Am Acad Dermatol. 2009;61(2):e5-e8.
32. Ostensen M. Pregnancy in psoriatic arthritis. Scand J Rheumatol. 1988;17(1):67-70.
33. Dunna SF, Finlay AY. Psoriasis: improvement during and worsening after pregnancy. Br J Dermatol. 1989;120(4):584.
34. Murase JE, Chan KK, Garite TJ, Cooper DM, Weinstein GD. Hormonal effect on psoriasis in pregnancy and post partum. Arch Dermatol. 2005;141(5):601-606.
35. Swanbeck G, Inerot A, Martinsson T, et al. Genetic counseling in psoriasis: empirical data on psoriasis among first-degree relatives of 3095 psoriatic probands. Br J Dermatol. 1997;137(6):939-942.
36. Weatherhead S, Robson SC, Reynolds NJ. Management of psoriasis in pregnancy. BMJ. 2007;334(7605):1218-1220.
37. Tauscher AE, Fleischer AB Jr, Phelps KC, Feldman SR. Psoriasis and pregnancy. J Cutan Med Surg. 2002;6(6):561-570.
38. Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol. 2008;59(2):295-315.
39. Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum. 2007;56(6):2092-2096.
40. Turner SJ, Levine L, Redman A. Lupus erythematosus and pregnancy. Obstet Gynecol. 1956;8:601-609.
41. Vinet E, Pineau C, Gordon C, Clarke AE, Bernatsky S. Systemic lupus erythematosus in women: impact on family size. Arthritis Rheum. 2008;59(11):1656-1660.
42. Ekblom-Kullberg S, Kautiainen H, Helve AT, Leirisalo-Repo M, Julkunen H. Reproductive health in women with systemic lupus erythematosus compared to population controls. Scand J Rheumatol. 2009;38(5):375-380.
43. Clowse ME. Lupus activity in pregnancy. Rheum Dis Clin North Am. 2007;33(2):237-252.
44. Chakravarty EF, Colón I, Langen ES, et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol. 2005;192(6):1897-1904.
45. Cortes-Hernandez J, Ordi-Ros J, Paredes F, et al. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology (Oxford). 2002;41(6):643-650.
46. Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum. 2005;52(2):514-521.
47. Tincani A, Bazzani C, Zingarelli S, Lojacono A. Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment. Semin Thromb Hemost. 2008;34(3):267-273.
48. Lassere M, Empson M. Treatment of antiphospholipid syndrome in pregnancy-a systematic review of randomized therapeutic trials. Thromb Res. 2004;114(5-6):419-426.
49. Izmirly PM, Rivera TL, Buyon JP. Neonatal lupus syndromes. Rheum Dis Clin North Am. 2007;33(2):267-285.
50. Llanos C, Izmirly PM, Katholi M, et al. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum. 2009;60(10):3091-3097.
51. Buyon JP, Clancy RM, Friedman DM. Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. Nat Clin Pract Rheumatol. 2009;5(3):139-148.
52. Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 2003;48(11):3207-3211.
53. Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001;10(6):401-404.
54. Sibai BM. Imitators of severe pre-eclampsia. Semin Perinatol. 2009;33(3):196-205.
55. Cárdenas-Mondragón G, Ulloa-Aguirre A, Isordia-Salas I, Goffin V, Leaños-Miranda A. Elevated serum bioactive prolactin concentrations in patients with systemic lupus erythematosus are associated with disease activity as disclosed by homologous receptor bioassays. J Rheumatol. 2007;34(7):1514-1521.